Clinical trial
Japanese BAY80-6946 Monotherapy Phase I Study
NCT01404390 · Bayer, Industry · Completed
Key facts
| NCT number | NCT01404390 |
|---|---|
| Title | Japanese BAY80-6946 Monotherapy Phase I Study |
| Official title | An Open Label, Single Centre, Phase I Study of PI3K Inhibitor BAY80-6946 to Evaluate the Safety, Tolerability and Pharmacokinetics in Japanese Patients With Advanced or Refractory Solid Tumours |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasms |
| Intervention type | Drug |
| Interventions | BAY80-6946 |
| Enrollment | 10 |
| Start date | Aug 18, 2011 |
| Primary completion | Mar 22, 2012 |
| Completion | Jul 12, 2012 |
| First posted | Jul 28, 2011 |
| Last update posted | Dec 14, 2017 |
| Countries | Japan |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: